Comparing SG&A Expenses: TG Therapeutics, Inc. vs Novavax, Inc. Trends and Insights

Biotech SG&A Expenses: Novavax vs. TG Therapeutics

__timestampNovavax, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 20141992800024518692
Thursday, January 1, 20153084200019886580
Friday, January 1, 20164652700012631689
Sunday, January 1, 20173445100021977998
Monday, January 1, 20183440900020759000
Tuesday, January 1, 20193441700020838000
Wednesday, January 1, 2020145290000121812000
Friday, January 1, 2021298358000152137000
Saturday, January 1, 202248869100083231000
Sunday, January 1, 2023468946000122706000
Loading chart...

In pursuit of knowledge

SG&A Expenses: A Tale of Two Biotechs

In the competitive world of biotechnology, managing expenses is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of TG Therapeutics, Inc. and Novavax, Inc. from 2014 to 2023. Over this period, Novavax's SG&A expenses surged by over 2,200%, peaking in 2022, reflecting its aggressive expansion and marketing strategies. In contrast, TG Therapeutics saw a more modest increase of around 400%, with a notable spike in 2021. This divergence highlights different strategic approaches: while Novavax invested heavily in scaling operations, TG Therapeutics maintained a more conservative expenditure. Understanding these trends offers insights into each company's operational priorities and market positioning. As the biotech landscape evolves, monitoring such financial metrics can provide valuable foresight into future industry shifts.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025